Thomas Kaercher

892 total citations
34 papers, 689 citations indexed

About

Thomas Kaercher is a scholar working on Public Health, Environmental and Occupational Health, Ophthalmology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Thomas Kaercher has authored 34 papers receiving a total of 689 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Public Health, Environmental and Occupational Health, 16 papers in Ophthalmology and 16 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Thomas Kaercher's work include Ocular Surface and Contact Lens (26 papers), Corneal Surgery and Treatments (12 papers) and Glaucoma and retinal disorders (11 papers). Thomas Kaercher is often cited by papers focused on Ocular Surface and Contact Lens (26 papers), Corneal Surgery and Treatments (12 papers) and Glaucoma and retinal disorders (11 papers). Thomas Kaercher collaborates with scholars based in Germany, United Kingdom and United States. Thomas Kaercher's co-authors include Claus Rodemer, Felix Wieland, Karin Gorgas, Thanh-Phuong Thai, Hauke Werner, Britta Brügger, Wilhelm W. Just, Klaus‐Armin Nave, Philipp Steven and Sonja Krösser and has published in prestigious journals such as Human Molecular Genetics, Vision Research and British Journal of Ophthalmology.

In The Last Decade

Thomas Kaercher

33 papers receiving 673 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Kaercher Germany 14 354 264 177 162 77 34 689
Masataka Kawai Japan 14 256 0.7× 77 0.3× 183 1.0× 177 1.1× 29 0.4× 17 503
Burkhardt S. Schüett Australia 10 180 0.5× 119 0.5× 71 0.4× 61 0.4× 60 0.8× 16 436
S Hodson United Kingdom 12 163 0.5× 180 0.7× 138 0.8× 280 1.7× 17 0.2× 27 559
Fabio Bignami Italy 12 241 0.7× 118 0.4× 116 0.7× 218 1.3× 23 0.3× 20 608
Anthony Mukwaya Sweden 17 103 0.3× 222 0.8× 175 1.0× 248 1.5× 13 0.2× 27 647
Marlies Gijs Netherlands 12 164 0.5× 112 0.4× 128 0.7× 196 1.2× 61 0.8× 35 465
Jaap A. van Best Netherlands 16 274 0.8× 125 0.5× 409 2.3× 325 2.0× 12 0.2× 38 684
W. Göttinger Austria 13 190 0.5× 95 0.4× 235 1.3× 263 1.6× 28 0.4× 43 510
George E. Marak United States 20 62 0.2× 347 1.3× 711 4.0× 109 0.7× 2 0.0× 55 1.1k

Countries citing papers authored by Thomas Kaercher

Since Specialization
Citations

This map shows the geographic impact of Thomas Kaercher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Kaercher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Kaercher more than expected).

Fields of papers citing papers by Thomas Kaercher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Kaercher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Kaercher. The network helps show where Thomas Kaercher may publish in the future.

Co-authorship network of co-authors of Thomas Kaercher

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Kaercher. A scholar is included among the top collaborators of Thomas Kaercher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Kaercher. Thomas Kaercher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kaercher, Thomas, et al.. (2024). Pooled results from two pivotal randomized controlled clinical trials: ESSENCE-1 and ESSENCE-2 to assess efficacy and safety of a water-free ciclosporin 0.1% formulation for the treatment of dry eye disease. Graefe s Archive for Clinical and Experimental Ophthalmology. 263(4). 1051–1060. 2 indexed citations
2.
Jacobi, Christina, et al.. (2022). A Water-Free Omega-3 Fatty Acid Eye Drop Formulation for the Treatment of Evaporative Dry Eye Disease: A Prospective, Multicenter Noninterventional Study. Journal of Ocular Pharmacology and Therapeutics. 38(5). 348–353. 11 indexed citations
3.
Kaercher, Thomas, et al.. (2022). Topical Omega-3 Polyunsaturated Fatty Acids for the Treatment of Dry Eye – Results from a Pilot Randomized Controlled Masked-Observer Study. Clinical ophthalmology. Volume 16. 4021–4031. 2 indexed citations
4.
Doan, Serge, Z Zagórski, Meltem Yağmur, et al.. (2020). Eyelid Disorders in Ophthalmology Practice: Results from a Large International Epidemiological Study in Eleven Countries. Ophthalmology and Therapy. 9(3). 597–608. 5 indexed citations
5.
Steven, Philipp, Albert J. Augustin, Gerd Geerling, et al.. (2017). Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease Due to Meibomian Gland Disease. Journal of Ocular Pharmacology and Therapeutics. 33(9). 678–685. 42 indexed citations
6.
Steven, Philipp, Dieter Scherer, Sonja Krösser, et al.. (2015). Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease—A Prospective, Multicenter Noninterventional Study. PubMed Central. 55 indexed citations
7.
Kaercher, Thomas, et al.. (2014). A prospective, multicenter, noninterventional study of Optive Plus® in the treatment of patients with dry eye: the prolipid study. Clinical ophthalmology. 8. 1147–1147. 22 indexed citations
8.
Brémond‐Gignac, Dominique, Paolo Emilio Bianchi, R. Messaoud, et al.. (2014). Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent bacterial conjunctivitis. British Journal of Ophthalmology. 98(6). 739–745. 14 indexed citations
9.
Kaercher, Thomas, et al.. (2013). Richtige Kontaktlinsenhygiene. Der Ophthalmologe. 110(6). 522–527. 1 indexed citations
10.
Kaercher, Thomas, P. Buchholz, & Friedemann Kimmich. (2009). Treatment of patients with keratoconjunctivitis sicca with Optive: results of a multicenter, open-label observational study in Germany.. PubMed. 3. 33–9. 29 indexed citations
11.
Kaercher, Thomas & Anthony J. Bron. (2008). Classification and Diagnosis of Dry Eye. Developments in ophthalmology. 41. 36–53. 23 indexed citations
12.
Brewitt, H., Thomas Kaercher, & Florian Rüfer. (2008). Trockenes Auge und Blepharitis. Klinische Monatsblätter für Augenheilkunde. 225(2). R15–R36. 10 indexed citations
13.
Kaercher, Thomas & H. Brewitt. (2004). Blepharitis. Der Ophthalmologe. 101(11). 1135–1148. 11 indexed citations
14.
Kaercher, Thomas. (2004). Ocular symptoms and signs in patients with ectodermal dysplasia syndromes. Graefe s Archive for Clinical and Experimental Ophthalmology. 242(6). 495–500. 57 indexed citations
15.
Rodemer, Claus, Thanh-Phuong Thai, Britta Brügger, et al.. (2003). Inactivation of ether lipid biosynthesis causes male infertility, defects in eye development and optic nerve hypoplasia in mice. Human Molecular Genetics. 12(15). 1881–1895. 188 indexed citations
16.
Kaercher, Thomas, et al.. (1999). How the most common preservative affects the Meibomian lipid layer. Orbit. 18(2). 89–97. 6 indexed citations
17.
Kaercher, Thomas, et al.. (1995). 2231 Brewster angle microscopy. Vision Research. 35. S97–S97. 1 indexed citations
18.
Kaercher, Thomas, et al.. (1994). Brewster angle microscopy. International Ophthalmology. 17(6). 341–348. 56 indexed citations
19.
Kaercher, Thomas, et al.. (1994). Biophysical behaviour of the infant Meibomian lipid layer. International Ophthalmology. 18(1). 15–19. 26 indexed citations
20.
Kaercher, Thomas, et al.. (1986). [Determination of the layer thickness of secretions of the meibomian glands by in vitro conditions].. PubMed. 83(1). 90–4. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masataka Kawai Breakdown of academic impact, for papers by Burkhardt S. Schüett Breakdown of academic impact, for papers by S Hodson Breakdown of academic impact, for papers by Fabio Bignami Breakdown of academic impact, for papers by Anthony Mukwaya Breakdown of academic impact, for papers by Marlies Gijs Breakdown of academic impact, for papers by Jaap A. van Best Breakdown of academic impact, for papers by W. Göttinger Breakdown of academic impact, for papers by George E. Marak
Rankless by CCL
2026